---
schema_version: "secwatch.filing_event.v1"
accession: "0001504337-23-000039"
form_type: "8-K"
ticker: "CLW"
cik: "0001441236"
company_name: "Clearwater Paper Corp"
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T05:46:25.866275+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clearwater Paper Q3 adjusted net income up to $37M; tissue strength boosts Consumer Products

## Summary
- Net sales of $520M, down 3% YoY; net income of $37M ($2.17 diluted EPS) vs $21M a year ago.
- Adjusted EBITDA of $81M (15% margin) vs $77M in Q3 2022; Consumer Products segment EBITDA doubled to $46M.
- Pulp & Paperboard segment sales fell 13% to $261M on lower volumes and prices; operating income $43M vs $64M.
- Plans to redeem 2025 notes in Q4 using new term loan, cash, and ABL; repurchased $5M shares; net debt reduced $69M.
- Company projects continued tissue strength into 2024 with gradual paperboard recovery; refinancing improves financial flexibility.

## SEC filing metadata
- accession: 0001504337-23-000039
- form_type: 8-K
- ticker: CLW
- cik: 0001441236
- company_name: Clearwater Paper Corp
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1441236/000150433723000039/0001504337-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1441236/000150433723000039/clw-20231030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001504337-23-000039
- JSON: https://secwatch.observer/filing/0001504337-23-000039.json
- Plain text: https://secwatch.observer/filing/0001504337-23-000039.txt

## Key facts
- Earnings Releases
  Clearwater Paper Corp reported the third quarter and nine months ended September 30, 2023 results: revenue Net sales of $520 million, net income Net income of $37 million, or $2.17 per diluted share, EPS $2.17 per diluted share.
  - Period: the third quarter and nine months ended September 30, 2023
  - Revenue: Net sales of $520 million
  - Net income: Net income of $37 million, or $2.17 per diluted share
  - EPS: $2.17 per diluted share
  - Result: reported results
  source text: months ended September 30, 2023. THIRD QUARTER HIGHLIGHTS • Outstanding performance driven by strong operational results and continued market strength in tissue • Net sales of $520 million, down 3% from the third quarter of last year • Net income of $37 million, or $2.17 per diluted share • Adjusted net income of $37 million, $6 million higher than the third
  evidence_url: https://www.sec.gov/Archives/edgar/data/1441236/000150433723000039/0001504337-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.